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http://www.translational-medicine.com/content/12/1/234RESEARCH Open AccessmiR-10b is overexpressed in hepatocellular
carcinoma and promotes cell proliferation,
migration and invasion through RhoC, uPAR
and MMPs
Cheng-gong Liao1,2†, Ling-min Kong3†, Ping Zhou1, Xiu-li Yang1, Jian-guo Huang1, He-long Zhang2* and Ning Lu1*Abstract
Background: Recently, miR-10b is identified as a miRNA highly expressed in many human cancers, promoting cell
migration and invasion. However, the specific function of miR-10b in hepatocellular carcinoma (HCC) is unclear at
this point.
Methods: The miR-10b expression levels in 60 paired different TNM Stage HCC tumor tissues compared with adjacent
non-tumor (ANT) tissues, normal tissue control (8 benign tumor and 7 normal liver tissues), 3 normal liver and 7 HCC cell
lines were measured by real-time quantitative RT-PCR and to evaluate their association with HCC clinicopathologic
features. Invasion assay, MTT proliferation assay and wound-healing assay were performed to test the invasion and
proliferation of HCC cell after transfection. The effect of miR-10b on HCC in vivo was validated by murine xenograft model.
Results: We found that miR-10b expression was increased in human HCC tissues and cell lines compared with
normal control, respectively. The expression of miR-10b was correlated with HCC metastatic ability. Overexpression of
miR-10b in MHCC-97L cells increased cell motility and invasiveness, whereas inhibition of miR-10b in MHCC-97H cells
reduced cell motility and invasiveness in vitro and in vivo. We also showed that HOXD10 was negatively regulated by
miR-10b at the posttranscriptional level, via a specific target site within the 3′UTR by luciferase reporter assay.
Furthermore, we found that miR-10b induced HCC cell invasion and migration by modulating the HOXD10 target
gene RhoC, uPAR, MMP-2 and MMP-9 expression.
Conclusions: Our results suggested that miR-10b was overexpressed in HCC and promoted HCC cell migration and
invasion through the HOXD10/ RhoC/ uPAR/ MMPs pathway which may provide a novel bio-target for HCC therapy.
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Hepatocellular carcinoma (HCC) is one of the most
common malignancies and leading causes of cancer-related
death worldwide, especially in Asian Pacific regions, which
has a highly invasive malignant behavior and recurrence
rate and remains one of the tumors most refractory to
treatment [1].* Correspondence: zhanghelong@medmail.com.cn; luning407@sina.com
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unless otherwise stated.MicroRNAs (miRNAs), which encode small non-coding
RNAs of approximately 22 nucleotides, are now recognized
as a very large gene family. Mature miRNAs are thought to
regulate the negative expression of a large number of genes
carrying target sites within 3′ untranslated regions (UTR)
[2]. Recent studies demonstrate that miRNAs may act
as activators of tumor metastasis by acting on multiple
signaling pathways involved in metastasis [3,4]. Among
these miRNAs, miR-10b is first reported to induce breast
cancer cell invasion and metastasis [3], which is also
found to be associated with tumor invasive potential in
pancreatic cancer [5], glioma [6], nasopharyngeal carcinoma
[7], esophageal cancer [8] and neurofibromatosis [9].. This is an Open Access article distributed under the terms of the Creative
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factor TWIST1, proceeds to inhibit translation of mRNA
of HOXD10, a transcription factor already known for its
roles in cell motility [10], resulting in increased expression
of a pro-metastatic gene, RhoC and tumor invasive fac-
tors, urokinase-type plasminogen activator receptor
(uPAR) [6]. Nowadays, MMPs have also been reported
participating in the miR-10b mediated tumor invasion and
metastasis [11]. In addition a study detecting the micro-
RNA profiling in hepatocellular tumors compared to
benign hepatic tumors and non-tumor liver tissues shown
that the expression of miR-10b was increased in HCC
[12,13]. But the exact function of miR-10b in HCC is
still unknown.
In this study, we first measured miR-10b expression
levels in different TNM stage HCC tumor tissues
compared with normal liver tissues, and HCC cell
lines. Then, we identified the role of miR-10b in HCC cell
migration and invasion; furthermore, we also examined the
direct binding target of miR-10b. Finally, tumor invasive
factors RhoC, uPAR, MMP-2 and MMP-9 were also
measured. Thus, our data suggested important roles
for miR-10b in HCC development and implicate this
miRNA’s potential application as a target for cancer
therapies.
Materials and methods
HCC and normal liver tissues
Sixty paired tissue specimens of HCC and adjacent
non-tumor (ANT) tissues were obtained from Department
of Hepatobiliary Surgery in Urumqi General Hospital of
Lanzhou Military Command of PLA (Urumqi, China).
Eight benign tumor tissues and seven fresh normal liver
tissues were also collected as control. Informed consent
was obtained from each patient. All the liver samples were
divided into 5 groups: non-metastatic HCC tissues (NHCC,
patients diagnosed as TNM stage I-II, n = 20), low
metastatic HCC tissues (LHCC, patients diagnosed as
TNM stage III-IVA with intrahepatic metastasis or regional
lymph node metastasis, n = 26), high metastatic HCC
tissues (HHCC, patients diagnosed as TNM stage IVB with
distance metastasis, n = 14), benign tumor tissues (BT,
patients diagnosed as hepatic haemangioma, n = 8), and
normal liver tissues (NL, n = 7). All of the tissues were
obtained at the time of surgery and immediately stored in
liquid nitrogen until use.
Cell lines and culture conditions
The following cell lines were used in this study: human
normal liver cell QZG [14], QSG-7701 [15] and HL-7702
[16]; human hepatocellular carcinoma cell lines: HepG2,
BEL-7402, FHCC-98, SMMC-7721, HCC-9724, MHCC-97H
(HCC cells with high metastatic potential) and MHCC-97L
(HCC cells with low metastatic potential) [17]. All cell lineswere purchased from Shanghai Institute for Biological
Sciences (Shanghai, China). All cell lines were routinely
cultured in RPMI-1640 medium or DMEM medium
(Hyclone Laboratories, Logan, UT) supplemented with
10% fetal calf serum (Gibco BRL, Rockville, MD, USA) at
37°C in a humidified atmosphere of 5% CO2.
Real-time quantitative RT-PCR
Total RNA was isolated from tissues and cell lines by
using TRIzol reagent (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. Reverse
transcription was performed using the Prime-Script RT
reagent kit (TaKaRa, Otsu, Japan). miR-10b was reverse
transcribed by the looped primer, which binds to six
nucleotides at the 3′ portion of miR-10b molecules.
Reverse transcriptions of RhoC, uPAR, MMP-2 and
MMP-9 mRNA were performed according to the manu-
facturer’s protocol. Real time PCR was performed using
SYBR Premix Ex Taq™ II kit (TaKaRa) according to the
manufacturer’s protocol on an MX3005P QPCR system
(Stratagene, La Jolla, CA, USA). The U6 small nuclear RNA
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA were used as internal controls for miR-10b and
other gene mRNA, respectively. All of the reactions were
run in triplicate. The delta-Ct method [18] for relative
quantification of gene expression was used to determine
miRNAs and mRNA expression levels. The looped RT
primer for miR-10 was GTC GTA TCC AGT GCG TGT
CGT GGA GTC GGC AAT TGC ACT GGA TAC GAC
CAC AAA. The PCR primers for miR-10b were GGA TAC
CCT GTA GAA CCG AA and CAG TGC GTG TCG
TGG AG T. The primers for U6 were TGG GGT TAT
ACA TTG TGA GAG GA and GTG TGC TAC GGA
GTT CAG AGG TT. The primers for RhoC mRNA were
ATG GCT GCA ATC CGA AAG and GAT CTC AGA
GAATGG GAC AGC. The primers for uPAR mRNA were
TCT ATC CGG AGC AGC TGA AAA and CGT GTA
GAC GCC TGG CTT GT. The primers for MMP-2
mRNA were CAG GGA ATG AGT ACT GGG TCT ATT
and ACT CCA GTT AAA GGC AGC ATC TAC). The
primers for MMP-9 mRNA were AAT CTC TTC TAG
AGA CTG GGA AGG AG and AGC TGA TTG ACT
AAA GTA GCT GGA. The primers for GAPDH mRNA
were GGT CGG AGT CAA CGG ATT TG and ATG AGC
CCC AGC CTT CTC CAT [8].
Plasmid construction
For the over-expression of miR-10b, genomic fragment
of Homo sapiens miR-10b precursor was amplified by
PCR using the primer pairs: 5′-GGC GGA TCC CAA
GCC CAT TAG GCT ACC TG-3′ and 5′- CCG GAA
TTC TGA GGA GCT TCT GGA GAG GA -3′ [8].
The PCR product was cloned into pcDNA3.1 (Invitrogen)
named as pcDNA3.1-miR-10b. 3′UTR segment of HOXD10
Liao et al. Journal of Translational Medicine 2014, 12:234 Page 3 of 10
http://www.translational-medicine.com/content/12/1/234was subcloned into the pmirGLO vector (Promega, Madison,
WI, USA) immediately downstream of the stop codon
of the luciferase gene. The mutant construct of HOXD10
3′UTR was generated using a QuickChange mutagenesis
kit (Stratagene, La Jolla, CA, USA) [3]. Wild-type and
mutant inserts were confirmed by sequencing.
Cell transfection
Cultured cells were transfected with miR-10b expression
vector, antisense miR-10b (anti-miR-10b), scramble miRNA
using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s protocol. miRNA inhibitor was chemically
enhanced by 2′O-4′C-methylene (2′-OME) modification.
The miR-10b inhibitors and scramble miRNA were designed
and synthesized in GenePharma Inc. (Shanghai, China). The
sequence was described as before [11].
Luciferase reporter assay
The cells of 80% confluence in 24-well plates were
transiently transfected with firefly luciferase reporter
gene constructs and miR-10b expressing plasmid. After
48 h, luciferase activity was measured using a dual luciferase
reporter assay system according to the manufacturer’s
protocol (Promega), normalized for transfection efficiency
by co-transfecting with pRL-TK.
Cell proliferation assay
Cells were plated in sextuplicate in 96-well plates
(2 × 103 per well) in 100 μL complete medium and
allowed to attach overnight. 3-(4,5-Dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide (MTT) (20 μL at
5 mg/mL; Sigma, St. Louis, MO) was added every 24 h
and incubated for 4 h. The supernatant was discarded, the
precipitate was dissolved in 200 μL dimethyl sulfoxide
(DMSO), and plates were read with a microplate reader at
570 nm [19].
Wound-healing assay
The wound-healing assay was used to evaluate the tumor
cell motility capacity. Briefly, 1 × 106 cells were seeded in
six-well plates, cultured overnight, and transfected with
miR-10b or miR-10b inhibitor and the respective controls.
When the culture had reached nearly 90% confluency, the
cell layer was scratched with a sterile plastic tip and then
washed with culture medium twice and cultured again for
up to 48 h with serum-reduced medium containing 1%
FBS. At different time points, photographic images of
the plates were acquired under a microscope and the
data were summarized based on sextuple assays for each
experiment.
In vitro invasion and migration assay
MilliCell (12 mm diameter with 8 μm pores) chambers
(Millipore, Bedford, MA, USA) were pre-coated withMatrigel (BD, Bedford, MA, USA) on the upper side. A
total of 1 × 105 serum-starved HCC cells were added to
the upper compartment in medium supplemented with
0.1% serum, and the chambers were placed into 24-well
plates with medium containing 10% serum. After 24 h at
37°C, invaded cells on the lower membrane surface were
fixed and stained with 0.1% crystal violet. Invasive activity
was quantified by counting nine high-power fields (HPFs,
400×) per chamber. Mean values were obtained from at
least three individual chambers for each experimental
point per assay. The migration assay is the same with
invasion assay excepting no matrigel was used and
the permeating time for cells was 12 hours.
In vivo proliferation assay
BALB/c nude mice at 4 to 6 weeks of age were provided
by the Laboratory Animal Research Center of Fourth
Military Medical University (FMMU), and the animal
study was reviewed and approved by Animal Care and
Use Committee of FMMU. A total of 5 × 106 MHCC-
97L cells stably expressing miR-10b were resuspend in
Matrigel (BD, 1 mg/ml) and injected subcutaneously into
nude mice. 42 days after injection, the mice were sacri-
ficed. Tumor volume was weekly determined using dir-
ect measurement and calculated using the formula
length × width2/2.
Western blot
Western blots were performed according to standard
protocols using Immobilon-P PVDF membranes (Millipore).
For immunoblotting, membranes were incubated with the
primary antibody (0.5 μg/mL) for 2 h, followed by a 1 h
incubation with HRP conjugated secondary antibody
(1:5000). The primary antibodies against HOXD10, RhoC,
uPAR, MMP-2, MMP-9 or tubulin were purchased from
Santa Cruz Corporation (Santa Cruz, CA, USA). Finally,
the blots were washed and the signals were visualized using
the ECL plus Kit (Amersham, Buckinghamshire, UK).
Statistical analysis
Each experiment was performed independently at least
twice with similar results; one representative experiment
was presented. All statistical analyses were performed
using the SPSS 16.0 statistical software package (SPSS,
Chicago, IL, USA). The significance of the data was
determined using Student’s t test. One-way ANOVA was
used to compare the miR-10b expression in different
groups. All the statistical tests were two-sided, and a
P value <0.05 was considered significant.
Results
miR-10b is over-expressed in HCC tissues and cell lines
The expression levels of miR-10b were first evaluated in
sixty paired of HCC and ANT tissues by real time
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levels were overexpressed in HCC tissues than those
in ANT tissues. Then we divided all the liver samples
into five groups depending on their pathological diagnosis.
When expression levels of miR-10b were compared
between subgroups, miR-10b was significantly higher in
HCC (NHCC, LHCC and HHCC) groups compared to
the normal liver (BT and NL) groups and miR-10b
expression was positively correlated with the tumor’s
stage (Figure 1b). The expression of miR-10b in metastatic
HCC tissues (HHCC and LHCC) was significantly higher
than in non-metastatic HCC tissues (NHCC, Figure 1c),
which indicated that the miR-10b expression was correlated
with the HCC metastatic ability.
We also detected the miR-10b expression in HCC and
normal liver cell lines. We performed real-time RT-PCR
on a panel of seven HCC and three normal liver cell
lines. As shown in Figure 1d, miR-10b expression levels
in HCC cell lines were significantly higher than those of
normal liver cell lines. miR-10b expression in MHCC-97H,
FHCC-98, SMMC-7721 and HCC-9724 cells was relatively
higher. In contrast, expression levels of miR-10b in HepG2,
BEL-7402 and MHCC-97L cells were relatively lower. TheFigure 1 miR-10b is over-expressed in HCC tissues and cell lines. (a) The
by real-time quantitative RT–PCR, and the U6 small nuclear RNA was used as a
differences between the HCC and ANT tissues. (b) The expression of miR-10b i
counted as control. One-way ANOVA was used to analyze the significant differ
(HHCC and LHCC) tissues and non-metastatic HCC (NHCC) tissues. The express
level of miR-10b in HCC tissues to the expression level of miR-10b in ANT tissu
relative levels of miR-10b in the seven HCC and three normal liver cell lines. Onhigher expression of miR-10b in HCC cells with high
metastatic potential suggested a causal role for miR-10b in
the migration and invasion of HCC cells.
miR-10b promotes HCC cell proliferation, migration and
invasion
To investigate whether miR-10b regulates HCC cell
migration and invasion, we selected MHCC-97H cells,
which show strong migration and invasion potential,
and MHCC-97L cells, which show weak migration and in-
vasion potential, for further study. First, we performed
loss-of-function and gain-of-function analysis. miR-10b
inhibitor was transfected into MHCC-97H cell to reduce
miR-10b expression, while miR-10b expression vector
was transfected into MHCC-97L cell to increase miR-
10b expression. Then we analyzed miR-10b levels
after transfection by real-time RT-PCR and found that
miR-10b levels were significantly reduced by the miR-10b
inhibitors (decreased about 0.57 fold compared with
the control cells, P < 0.05, Figure 2a) and elevated by
the miR-10b expression vector (increased about 2.75
fold compared with the control in the MHCC-97L cells,
P < 0.01, Figure 2a).relative levels of miR-10b in sixty paired of HCC samples were measured
n internal control. Student’s t test was used to analyze the significant
n the five tissue groups. Benign tumor tissues and normal liver tissues were
ences among the groups. (c) The expression of miR-10b in metastatic HCC
ion of miR-10b was calculated as the normalized ratio of the expression
es. Student’s t test was used to analyze the significant differences. (d) The
e-way ANOVA was used to analyze the significant differences.
Figure 2 miR-10b promotes HCC cell migration and invasion. (a) In MHCC-97L cells transfected with pcDNA3.1-miR-10b and control vector
and in MHCC-97H cells transfected with anti-miR-10b, miR-10b expression was measured by real-time quantitative RT-PCR. (b) Proliferation of
MHCC-97H and MHCC-97L cells transfected with miR-10b inhibitor or miR-22 overexpression vector was measured in the indicated time periods
using the MTT assay. (c) Wound healing assay of MHCC-97H and MHCC-97L cells transfected with miR-10b inhibitor or miR-22 overexpression vec-
tor. (d) Migration and invasion potential in both cell lines treated as above were measured by Transwell assays. The results were the means of
three independent experiments ± S.D. * P < 0.05, Student’s t test was used to analyze the significant differences.
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HCC cells, MTT proliferation assay were performed with
MHCC-97H cells transfected with miR-10b inhibitor and
MHCC-97L cells transfected with miR-10b expression vec-
tor, respectively. The results showed that miR-10b could
significantly promoter HCC cell proliferation (P <
0.05, Figure 2b). Next, the wound-healing assay
showed that MHCC-97H cells with miR-10b inhibitor
presented a slower closing of scratch wound, compared
with the negative control. There was a quicker closing in
MHCC-97L cells with miR-10b overexpression (P < 0.05,
Figure 2c).
Then we investigated whether miR-10b could enhance
HCC cell invasion, transwell assays were performed. The
results showed that the inhibition of miR-10b expression
led to significant reduction in invasion compared to the
control cells (P < 0.05, Figure 2d). Then, we utilized
miR-10b expression vector to up-regulate the level of
miR-10b in MHCC-97L cells, which led to a 2.02 fold
increase in invasion (P < 0.05, Figure 2d). Next, the ef-
fect of miR-10b on the migration of HCC cells was
determined by transwell migration assay. In line with
the results from the above invasion assays, miR-10b also
enhanced the migration of HCC cells (Figure 2d). These
observations indicated a positive role for miR-10b in mi-
gration and invasion of human HCC cell lines.We next asked whether miR-10b could promote HCC
development in vivo. Using HCC tumor models, the
control mice showed the apparent presence of primary
tumor, whereas those injected with miR-10b expression
vector increased the volume of tumors during the same
observation period (Figure 3). Judging from data between
the controls and miR-10b overexpressed groups at the
points of the experiment, miR-10b overexpression resulted
in a mean increasing in tumor growth.
HOXD10 is a direct target of miR-10b
HOXD10 has been reported to be regulated by miR-10b
in human breast cancer [3]. To verify whether miR-10b
directly targeted HOXD10 in HCC cell lines, luciferase
reporter assays were carried out. We constructed
pmirGLO-HOXD10-3′UTR and pmirGLO-HOXD10-3′
UTR-mut with a substitution of four nucleotides within
the miR-10b binding site (Figure 4a). Cotransfection of
MHCC-97L cells with pmirGLO-HOXD10-3′UTR and
pcDNA3.1-miR-10b caused a 0.46 fold decrease in the
luciferase activity compared with the negative con-
trol (P < 0.05). This suppression was rescued by the
four-nucleotide substitution in the core binding sites
(Figure 4b). The similar effect was also observed in
HepG2 cells (0.42 fold decrease compared to the
blank control, P < 0.05, Figure 4b).
Figure 3 miR-10b increases HCC growth in vivo. (a) Representative figures of tumors in negative control and miR-10b overexpression groups.
(b) Determination of tumor volumes at different time points. (c) After the final measure, the mice were sacrificed, and the tumors were excised.
Tumor volume was measured and calculated using the formula length × width2/2. Student’s t test was used to analyze the significant differences.
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MMPs expression via the target HOXD10 gene
To test whether miR-10b expression affected endogenous
HOXD10 expression, we transfected miR-10b inhibitor
and control plasmid into MHCC-97H, and an increase of
HOXD10 protein level was observed. Consistent with
these results, overexpression of miR-10b in MHCC-97L
cells showed a decrease in the HOXD10 protein level
(Figure 5a). Real-time RT-PCR showed that overexpression
or inhibition of miR-10b had no effect on HOXD10 mRNA
level (Figure 5b), which indicated the post-transcriptional
regulation of miR-10b on HOXD10 mRNA. Preview
studies have shown that miR-10b inhibits the translation
of HOXD10 mRNA, thereby affecting the expression of
downstream targets of this transcription factor. The
potential effectors of HOXD10 include RhoC, uPAR
and MMPs, which functions in invasion, migration and
metastasis [3,6,11]. To further investigate the signaling
pathway, we measured RhoC, uPAR, MMP-2 and MMP-9
protein expression levels after transfection with miR-10b
inhibitor in MHCC-97H cells. Expression of all genes was
decreased by the miR-10b inhibitor (Figure 5c), which
indicated that RhoC, uPAR, MMP-2 and MMP-9 were
regulated by miR-10b in HCC cell. Then, we examined
the levels of these migration and invasion factors after
transfection with miR-10b express vector in MHCC-97L
cells. The results showed that all of them were up-regulatedby miR-10b over-expression (Figure 5c). These results indi-
cated that miR-10b served as a tumor metastasis factor in
HCC cell through the HOXD10/ RhoC/ uPAR/ MMPs
pathway.
Discussion
In our study, we demonstrated that miR-10b expression is
increased in human HCC tissues and cell lines compared
with matching adjacent non-tumor tissue and normal liver
cell lines. The expression of miR-10b correlates with HCC
metastatic ability in vitro and in vivo. It is also demon-
strated that HOXD10 is negatively regulated by miR-10b at
the posttranscriptional level, via a specific target site within
the 3′UTR. miR-10b promotes HCC cell migration and
invasion through the HOXD10/ uPAR/ RhoC/ MMPs
pathway. Identification of miR-10b as an important
regulator of tumor cell migration and invasion emphasizes
an essential role of this miRNA in mediating hepatic
oncogenesis and tumor behavior.
Increased numbers of reports reveal the aberrant
expression of several miRNAs in tumors with a correlation
with certain oncogenes or tumor suppressors or in response
to chemotherapy or radiation [20-22]. Recently, a growing
number of miRNAs have been found to be either activators
or suppressors of tumor invasion and metastasis [23-26].
miR-10b was first discovered initiating breast cancer inva-
sion and metastasis [3]. However, the function of miR-10b
Figure 4 The HOXD10 3′UTR is a target of miR-10b. (a) Upper panel, predicted duplex formation between human HOXD10 3′UTR and miR-10b.
Lower panel, diagram of the luciferase reporter plasmids: plasmid with the full length wild-type HOXD10 3′UTR (pmirGLO-HOXD10-3′UTR) insert and
plasmid with a mutant HOXD10 3′UTR (pmirGLO-HOXD10-3′UTR-mut) which carried a substitution of four nucleotides within the miR-10b binding site.
(b) Luciferase activity assay demonstrates a direct targeting of the 3′UTR of HOXD10 by miR-10b. MHCC-97L and HepG2 cells were transfected with
pcDNA3.1-miR-10b and pmirGLO-HOXD10-3′UTR or pmirGLO-HOXD10-3′UTR-mut. pRL-TK Renilla was used for normalization of transfection efficiency.
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this study, we investigated the role and the functional target
of miR-10b in human hepatocellular carcinoma.
Firstly, we measured miR-10b expression levels in
different TNM stage HCC tumor tissues compared
with normal liver tissues, and HCC cell lines. Our results
showed that miR-10b expression levels were overexpressed
in HCC tissues than those in ANT tissues. The expression
of miR-10b in metastatic HCC tissues was significantly
higher than those in non-metastatic HCC tissues.
Furthermore, miR-10b expression in HCC cell with
high metastatic potential was statistically significantly
higher than that with high metastatic potential HCC cell.
These findings indicated that miR-10b is overexpressed in
HCC tissues and cells, and might play some role in the
invasion and migration of HCC cells.Also, because miR-10b expression of HCC cell line
MHCC-97H was high and MHCC-97L was relatively
low in our study, it is interesting to investigate the
association between miR-10b expression and the inva-
sive potential or migration levels using these cell
lines. We used antisense miR-10b, which could de-
crease miR-10b expression, and miR-10b expression
vector, which could increase miR-10b levels. When
transfected with the miR-10b inhibitor, MHCC-97H
cells lost their invasion potential while MHCC-97L
cells’ invasive ability was enhanced by the miR-10b
over-expression. The in vivo mice experiments also
proved role of miR-10b in HCC proliferation. These
results indicated that miR-10b could contribute to the
HCC progress through promoting tumor cell proliferation,
migration and invasion.
Figure 5 miR-10b modulates invasion factors RhoC, uPAR and MMPs expression via the target HOXD10 gene. (a) MHCC-97L cells were
transfected with pcDNA3.1-miR-10b and control vector. MHCC-97H cells were transfected with anti-miR-10b and nonsense sequence. Then, HOXD10
protein levels were analyzed by Western blot. (b) In parallel, HOXD10 mRNA in the two cell lines treated as above was measured by real time RT-PCR.
GAPDH served as internal control. (c) The protein expression levels of RhoC, uPAR, MMP-2 and MMP-9 were measured in the two cell lines treated as
above was measured by Western blot, respectively.
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its function and found that HOXD10 was a direct target
of miR-10b in HCC. Luciferase reporter assays showed
that miR-10b could bind to the 3′UTR of HOXD10
and down-regulate the luciferase activity. HOXD10, a
sequence-specific transcription factor, has been intimately
linked with the invasion and metastatic potential of
human breast cancer cells [3,27]. HOXD10 expression is
lost as a function of invasion and reintroduction of
HOXD10 restores non-tumorigenic phenotypes in invasive
breast cancer cells [27], suggesting that HOXD10 may play
a role as a suppressor of tumor invasive growth. Therefore,
HOXD10 is a direct and functional target of miR-10b
which may result in an increased expression of a cluster of
well characterized pro-metastatic genes.
miR-10b inhibits the translation of mRNA encoding
HOXD10, which modulates many genes that promote inva-
sion, migration, extracellular matrix remodeling and tumor
progression [10]. So we detected potential target genes of
HOXD10, including RhoC, uPAR, MMP-2 and MMP-9.
Among these, RhoC has been identified as an especially
important player in metastasis [28,29], and its expression
correlates with metastatic spread of various types of carcin-
omas [30-32]. Indeed, we found that miR-10b transduced
cells exhibited robust expression of RhoC protein, whereas
RhoC expression in the control cells was relatively low. The
uPAR has been reported playing a significant role with
regard to HCC progression and metastasis [33]. The
molecular role of uPAR in cancer progression is wellcharacterized. In addition to its participation in extra-
cellular matrix degradation, uPAR elicits a number of
nonproteolytic cellular responses involved in tumor
progression and angiogenesis, such as cell migration,
adhesion, differentiation, and proliferation [34,35]. One
hallmark of metastasis and invasive growth is the
transition of tumor cells from an epithelial to a
mesenchymal morphology, known as the epithelial–
mesenchymal transition (EMT) [36]. MMPs help cancer
cells spread by breaking down the extracellular matrix
(ECM) and other barriers [37]. MMP-2 and MMP-9
were previously reported to be involved in human
tumorigenesis and metastasis [38]. So, we transfected
miR-10b inhibitors and found that HOXD10 protein
levels were elevated while RhoC, uPAR, MMP-2 and
MMP-9 levels were decreased. The transfection of
miR-10b expression vector resulted in an opposite effect.
These results indicated that miR-10b served as a tumor
metastasis factor in HCC cell through the HOXD10/
RhoC/ uPAR/ MMPs pathway.
Conclusions
The present study provides evidence to support that
miR-10b, a microRNA overexpressed in HCC, inhibits
the expression of the HOXD10 post-transcriptionally by
binding to the 3′UTR of the HOXD10 mRNA, thereby
promoting the RhoC/ uPAR/ MMPs induced cell invasion
and migration. These findings imply that miR-10b might
be a valuable candidate for anticancer therapy.
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